Advertisement
Product › Details
Lynparza®
Next higher product group | olaparib | |
Status | 2014-12-18 registration start | |
Organisation | AstraZeneca plc (LSE: AZN) | |
Group | AstraZeneca (Group) | |
Organisation 2 | Kudos Pharmaceuticals Ltd. | |
Today | AstraZeneca (Group) | |
Group | AstraZeneca (Group) | |
Original research | University of Cambridge | |
Record changed: 2023-07-10 |
Advertisement
More documents for Lynparza®
- [1] Merck & Co., Inc.. (12/21/22). "Press Release: Lynparza (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer". Rahway, NJ....
- [2] AstraZeneca plc. (10/24/19). "Press Release: Year-to-Date and Q3 2019 Results"....
- [3] AstraZeneca plc. (5/8/18). "Press Release: Lynparza Tablets Receive EU Approval for the Treatment of Platinum-sensitive Relapsed Ovarian Cancer"....
- [4] AstraZeneca plc. (2/23/18). "Press Release: Lynparza Receives Positive EU CHMP Opinion in Platinum-sensitive Relapsed Ovarian Cancer"....
- [5] AstraZeneca plc. (1/12/18). "Press Release: Lynparza Approved by US FDA in Germline BRCA-mutated Metastatic Breast Cancer"....
- [6] AstraZeneca plc. (8/17/17). "Press Release: Lynparza Receives Additional and Broad Approval in the US for Ovarian Cancer"....
- [7] AstraZeneca plc. (7/27/17). "Press Release: H1 2017 Results"....
- [8] AstraZeneca plc. (7/27/17). "Press Release: AstraZeneca and Merck Establish Strategic Oncology Collaboration"....
- [9] AstraZeneca plc. (3/14/17). "Press Release: Lynparza Phase III SOLO-2 Data Demonstrate Progression-free Survival Benefit in BRCA-mutated Ovarian Cancer as Maintenance Therapy"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top